Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Oct 14;58(4):2100673.
doi: 10.1183/13993003.00673-2021. Print 2021 Oct.

A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19

Dave Singh  1 , Maxim Bogus  2 , Valentyn Moskalenko  3   4   5 , Robert Lord  6 , Edmund J Moran  7 , Glenn D Crater  7 , David L Bourdet  7 , Nathan D Pfeifer  7 , Jacky Woo  7 , Elad Kaufman  7 , David A Lombardi  7 , Emily Y Weng  7 , Tuan Nguyen  7 , Ashley Woodcock  6 , Brett Haumann  8 , Rajeev Saggar  9
Affiliations
Clinical Trial

A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19

Dave Singh et al. Eur Respir J. .

Abstract

The inhaled lung-selective pan-JAK inhibitor nezulcitinib appears generally well tolerated in hospitalised patients with severe #COVID-19, with trends for improved oxygenation and clinical status, shortened hospitalisation, and fewer deaths versus placebo https://bit.ly/35Xs1Rf

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: D. Singh reports personal fees from Theravance Biopharma during the conduct of the study; and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Genentech, GlaxoSmithKline, Glenmark, Menarini, Mundipharma, Novartis, Peptinnovate, Pfizer, Pulmatrix, Theravance Biopharma and Verona outside this work. Conflict of interest: M. Bogus is an employee of Arensia Exploratory Medicine SRL. Conflict of interest: V. Moskalenko is an employee of Arensia Exploratory Medicine, LLC. Conflict of interest: R. Lord reports an independent grant from Vertex Pharmaceuticals for an investigator-initiated study on gastro-oesophageal reflux, honoraria from the Manchester Adult CF Centre for speaking at a conference and travel awards from the European CF Society and British Thoracic Society. Conflict of interest: E.J. Moran is an employee of Theravance Biopharma US, Inc., and shareholder of Theravance Biopharma, Inc. Conflict of interest: G.D. Crater is a former employee of Theravance Biopharma US, Inc., and owns shares in Theravance Biopharma, Inc. Conflict of interest: D.L. Bourdet is an employee of Theravance Biopharma US, Inc., and shareholder of Theravance Biopharma, Inc. Conflict of interest: N.D. Pfeifer is an employee of Theravance Biopharma US, Inc., and shareholder of Theravance Biopharma, Inc. Conflict of interest: J. Woo is an employee of Theravance Biopharma US, Inc., and shareholder of Theravance Biopharma, Inc. Conflict of interest: E. Kaufman is an employee of Theravance Biopharma US, Inc., and shareholder of Theravance Biopharma, Inc. Conflict of interest: D.A. Lombardi is an employee of Theravance Biopharma US, Inc., and shareholder of Theravance Biopharma, Inc. Conflict of interest: E.Y. Weng is a former employee of Theravance Biopharma US, Inc., and owns shares in Theravance Biopharma, Inc. Conflict of interest: T. Nguyen is an employee of Theravance Biopharma US, Inc., and shareholder of Theravance Biopharma, Inc. Conflict of interest: A. Woodcock reports fees from Theravance Biopharma, Inc., for consulting on the study design. Conflict of interest: B. Haumann is a former employee of Theravance Biopharma UK Limited and shareholder of Theravance Biopharma, Inc. Conflict of interest: R. Saggar is an employee of Theravance Biopharma US, Inc., and shareholder of Theravance Biopharma, Inc.

References

    1. McElvaney OJ, McEvoy NL, McElvaney OF, et al. . Characterization of the inflammatory response to severe COVID-19 illness. Am J Respir Crit Care Med 2020; 202: 812–821. doi:10.1164/rccm.202005-1583OC - DOI - PMC - PubMed
    1. Sims JT, Krishnan V, Chang CY, et al. . Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19. J Allergy Clin Immunol 2021; 147: 107–111. doi:10.1016/j.jaci.2020.08.031 - DOI - PMC - PubMed
    1. Wiersinga WJ, Rhodes A, Cheng AC, et al. . Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 2020; 324: 782–793. doi:10.1001/jama.2020.12839 - DOI - PubMed
    1. World Health Organization . Corticosteroids for COVID-19: Living guidance – 2 September 2020. www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1 Date last accessed: 1 March 2021.
    1. Horby P, Lim WS, Emberson JR, et al. . Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021; 384: 693–704. doi:10.1056/NEJMoa2021436 - DOI - PMC - PubMed